An observational study in Metastatic Colorectal Cancer (mCRC), sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie. Recruiting at 7 sites in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-10.
Sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies in Colorectal Neoplasms with a site in Austria — 15 open to participants now, 20 under way, 7 of them phase 3. Colorectal Neoplasms · Austria.
Among the 103 studies in Colorectal Neoplasms with a site in Austria, this one is the 11th largest by planned enrollment of the 25 observational ones that give a count, is one of 3 that started in 2024, is one of 25 observational ones, reaches primary completion later than 19 of the 19 other live ones, and was the 95th registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →15 of the 103 studies in Colorectal Neoplasms with a site in Austria are open now. Recruiting first, the newest first:
EMD Serono Research & Development Institute, Inc. · Sites in Austria, United States, Argentina and 16 more countries
Ages 18+
Incyte Corporation · Sites in Austria, United States, Argentina and 19 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Austria, United States, Argentina and 22 more countries
Ages 18+
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Sites in Austria, Germany
Ages 18+
AbbVie · Sites in Austria, United States, Australia and 12 more countries
Ages 18+
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 32 · Phase 3 35 · Phase 4 1
First in 1998; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 250 across 1,444 observational studies indexed under Colorectal Neoplasms.
Median enrollment 273 across the 74 interventional studies, 300 across the 25 observational. Of the 74 that completed or were terminated, 34 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 103 have an industry lead sponsor. The 10 most frequent:
Arbeitsgemeinschaft medikamentoese Tumortherapie is the lead sponsor of 43 studies on the registry; 4 are open to participants now.
Arbeitsgemeinschaft medikamentoese Tumortherapie has 3 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Colorectal Neoplasms with a site in Austria that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01789229Medical University of ViennaEstablishment of a Tumor Bank for Tissue Samples | 2026-12 |
| NCT01763125Medical University of ViennaEstablishment of a Tumor Bank for Blood Samples | 2026-12 |
| NCT05176483ExelixisStudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors | 2027-01-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 103 studies in Colorectal Neoplasms with a site in Austria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Colorectal cancer (CRC) is the second leading cause of cancer-related death in the United States and Europe. Although selected patients with oligometastatic CRC undergo systemic therapy and surgery/local ablative therapy in curative intent, the treatment approach for the majority of metastatic CRC (mCRC) patients remains palliative with a median overall survival (OS) ranging between 9-38 months depending on various prognostic and predictive factors. Particularly in advanced stages (in the third line of therapy and beyond), interesting and promising results have recently been achieved with various treatment approaches. The aim of this registry is to establish a disease-specific registry to evaluate the treatment landscape of patients with mCRC who have already received at least two lines of therapy.
This registry aims at retrospectively and prospectively evaluating the treatment landscape and clinical outcome of mCRC ≥3L in a collective attempt by including multiple oncologic centers in Austria.
Patient medical, testing and treatment information will be obtained through extraction of data from existing patient medical charts. Longitudinal follow-up data, including survival and tumor progression, will also be extracted from patient medical charts. Imaging studies ≥3L will be centrally collected in a virtual "imaging-bank" and tumor tissue samples of deceased patients will be stored in a central "bio-bank". Additionally, further biomaterial (e.g. ctDNA samples or DNA from DPYD genotyping) may be requested from the centres in case of specific research questions. The patient follow-up data will be obtained until patient death or loss to follow-up.
For documentation in the registry, no further diagnostic or therapeutic measures are required than those already necessary in general. Participation in the registry must not interfere with treatment routines. Only routine data, which have already been recorded in the patients' medical charts, is transferred to the electronic Case Report Forms. To maintain patient confidentiality, each patient will be assigned a unique patient identifying number upon enrollment; this number will accompany the patients' medical and other registry information throughout the lifetime of the registry.
A written consent must be obtained prior to the input of data. No informed consent is required from deceased patients.
Data will be collected from all sites willing to participate.
Interested sites that treat patients in this indication will be invited to participate in this registry
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Overall Survival
Overall survival with the respective treatment protocols ≥3L
Time frame: 10 years
Progression free survival
Progression-free survival (PFS) with the respective treatments protocols ≥3L
Time frame: 10 years
Overall response rate (ORR)
Overall response rate (ORR) with the respective ≥3L treatment protocols
Time frame: 10 years
Blinded Independent Central Review (BICR)
Blinded Independent Central Review (BICR) based on the virtual imaging-bank
Time frame: 10 years
Identification of predictive biomarkers
Identification of predictive biomarkers for mCRC patient sub-cohorts of interest based on the centrally-located bio-bank
Time frame: 10 years
Started Oct 2024 (actual). Primary completion is estimated for Dec 2034, 122 months after the start.
Of 531 non-industry observational studies under Colorectal Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 132. This study's planned 122 months is above that.
Counting every sponsor, half of 648 studies reached it within 52 months; a quarter within 27 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Arbeitsgemeinschaft medikamentoese Tumortherapie